Company
Alpha Teknova, Inc. (TKNO)
Standardized SEC financial data for Alpha Teknova, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001850902 · NASDAQ · In Vitro & In Vivo Diagnostic Substances.
Gross margin
33.2%
Operating margin
-41.9%
Net margin
-42.6%
Revenue growth (YoY)
7.3%
Return on equity
-25.1%
ROIC
-17.6%
Free cash flow
-$9.8M
Debt / equity
0.19×
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $31.3M | $36.9M | $41.4M | $36.7M | $37.7M | $40.5M |
| Cost of revenue |
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.3M | $87.5M | $42.2M | $28.5M | $3.7M | $5.9M |
| Inventory |
Cash flow
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $2.5M | -$9.1M | -$27.4M | -$18.8M | -$12.4M | -$8.6M |
| Capital expenditures |
Get TKNO data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/TKNO/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/TKNO/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"